Drugs / JNJ-54175446
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT03088644 | Mar → Nov 2017 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT03058419 | Mar → May 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02902601 | Oct 2016 → Jun 2017 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02930694 | Oct → Dec 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02933762 | Sep → Nov 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02515955 | Aug 2015 → Mar 2016 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT02475148 | Jun → Oct 2015 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04116606 Comparator | Sep 2019 → Dec 2023 | major depressive disorder | CCTU-Core | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-54175446 | “A Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Participants” NCT02475148 ↗ |
| Action | Inhibit | “antagonist of the adenosine triphosphate (ATP)-gated P2X7 channel” NCT04116606 ↗1“P2X purinoceptor 7 antagonist” CHEMBL4079239 ↗ |
| Modality | Small molecule | — CHEMBL4079239 ↗ |
| Route | Oral | “after single oral dose administration” NCT02475148 ↗ |
| Target | P2RX7 | “P2X purinoceptor 7 antagonist” CHEMBL4079239 ↗ |